Crosstree Innovations in Pharmaceutical Development by Sven Boermeester

INFORMATION PACKET FOR THOUGHT LEADERS AND NOMINATED COMPANIES

Published by

I N N O V A T I O N S

I N

P H A R M A C E U T I C A L

D E V E L O P M E N T

I N N O V A T I O N S

I N

P H A R M A C E U T I C A L

D E V E L O P M E N T

WHAT IS THE PUBLICATION? Innovations in Pharmaceutical Development is a directory resource that highlights approximately 20 thought leaders and approximately 60 to 80 companies at the forefront of innovation in pharmaceutical development. Profiled companies and thought leaders are selected from nominations by a panel of six independent industry experts and three panelists from Crosstree. Panelist profiles are provided herein.

WHY CROSSTREE? Crosstreeâ&#x20AC;&#x2122;s strategic research and consulting division is publishing three Pharma Services Innovations directories for (i) Development, (ii) Commercial, and (iii) Supply Chain segments. Crosstree is publishing the directories to advance its thought leadership content, beginning with the Development segment. It is important to Crosstree that the directories are perceived as professional, high-quality industry resources, and not promotional advertorials.

WHAT IS THE COMMERCIAL MODEL? There is no cost or obligation for nominated companies to participate. The book will be sold as a directory to biopharmaceutical companies, investors, analysts, and other industry participants. Crosstree has partnered with Global Village, a directory publisher, to publish the directories. Global Village will offer nominated companies optional promotional products, which are further described in the back of this overview.

Crosstreeâ&#x20AC;&#x2122;s Innovations in Pharmaceutical Development is being developed and fully funded by Crosstree and Global Village. There is no cost or other obligation involved to participate.

I N N O V A T I O N S

I N

P H A R M A C E U T I C A L

D E V E L O P M E N T

SELECTION COMMITTEE

Shane Senior INNOVATIONS in Pharmaceutical Development Panelist

Stephen J. Sullivan INNOVATIONS in Pharmaceutical Development Panelist

Richard F. Cimino INNOVATIONS in Pharmaceutical Development Panelist

Richard J. Riegel INNOVATIONS in Pharmaceutical Development Panelist

Jeff Ellis INNOVATIONS in Pharmaceutical Development Panelist

Shane Senior has over 20 years of investment banking experience, with 15 of those years cultivating industry relationships with investors and strategic executives within pharma services.

Sullivan was President and CEO of Harlan Laboratories, a major pre-clinical CRO from 2006-2010. From 1999-2006 he headed most of the clinical divisions of Covance, Inc. Prior to Covance, Sullivan was Chairman, President and Chief Executive Officer of Xenometrix, Inc., a drug discovery tool company. Previously, he served in several senior management positions at Abbott Laboratories, including Vice President of Worldwide Marketing for Abbott Diagnostics, and Vice President and General Manager of the Diagnostic Assay Sector and also held senior management positions at Lyphomed, Inc., Dart and Kraft Inc., and Baxter International.

Mr. Richard F. Cimino is an independent consultant who focuses on growth equity in the Health Services sector. Mr. Cimino has served on several boards. Currently he is the Executive Chairman of TwoLabs Inc. and a Director of Evolution Research Group. Previously, Mr. Cimino was non-Executive Chairman of the Board of MedAvante Inc., a privately held pharma services sector company. Mr. Ciminos’ primary responsibilities as Chairman included; governance, strategy, succession planning and key initiative planning and implementation. Mr. Cimino also served as an independent director for BioClinca Inc. (NASDAQ: BIOC) for six years.

Richard J. Riegel leads LMC Advisory, LLC, which was established to provide advisory and consulting services for investors and organizations that are focused on high growth solutions opportunities in life sciences. Services provided and experiences include market assessment, buy-side advisory, board membership, and mentoring and advising company leadership teams on strategy, go-to-market and building equity value.

Jeff Ellis co-founded Crosstree Capital Partners in 2004 and is responsible for leading the firm’s coverage of diagnostic products and services, life sciences tools, and pharmaceutical testing laboratories.

Prior to co-founding Crosstree Capital Partners, Senior established the corporate finance practice at William R. Hough & Co. (later acquired by the Royal Bank of Canada) and spent six years providing M&A investment banking services with Citigroup. Senior has advised more than 150 companies and has managed or participated in more than 90 successful transactions. Senior is a CFA charterholder, member of the Chartered Financial Analyst Institute, and a member of the Drug Industry Association (DIA).

Sullivan has served on several public, private and not-for-profit boards and is currently Chairman of Interpace Diagnostics, Inc. (NASDAQ:IDXG), a molecular diagnostics lab, Chairman of MI Bioresearch, Inc., a venture-backed oncology discovery services company, Chairman of Analytical Lab Group LLC, comprised of three microbiology service companies, and Board Member of TransnetYX, Inc., the leader in genotyping of research models in drug development.

He is a CEO with a proven track record of successfully transforming solutions companies to higher growth, greater profitability and increased shareholder value. He serves as the vice chairman of the board of Phlexglobal, Inc. and he previously served as the company’s Chief Executive Officer before his retirement in early 2019. Under his four years of leadership, Phlexglobal grew significantly, improved profitability, established a significant services operation in Poland, and he led the sale process to new private equity ownership. He also serves on the Board of Advisors of Gens & Associates and Adaptive Clinical.

He has 20 years of advisory experience working with clients ranging from large multinational corporations to entrepreneur-owned companies. Ellis has successfully completed transactions throughout North America, Europe, and Asia. Prior to Crosstree, Ellis was employed as an investment banker with Banc of America Securities. Ellis holds a BS in finance from the University of Florida and a MBA from the University of South Florida.

I N N O V A T I O N S

I N

P H A R M A C E U T I C A L

D E V E L O P M E N T

Gordon Ryerson INNOVATIONS in Pharmaceutical Development Panelist

Richard Thomas INNOVATIONS in Pharmaceutical Development Panelist

Todd Grosshandler INNOVATIONS in Pharmaceutical Development Panelist

Dan Snyder INNOVATIONS in Pharmaceutical Development Panelist

Gordon Ryerson has over 20 years of investment banking and strategic consulting experience across the pharmaceutical, medical device and pharma services industries.

Former Board of Directors for Bracket, THREAD research, Signant Health, ProPharma Group and Advarra. Current Strategic Advisory Board Member for Genstar Capital and President & CEO R Ventures Inc., a consulting firm offering a wide range of investment, advisory and consulting services for investors and organizations that are focused on high growth services opportunities in healthcare, life sciences and technology.

Former Co-Founder and owner of Enthalpy Analytical, Executive Director of Sales at Covance (LabCorp’s Drug Development Business), President and CEO of Integrated Laboratory Systems and currently, Executive Vice President, Head of Commercialization at Montrose Environmental Group, a high-growth environmental services company with more than 50 locations and 1,200 employees throughout North America.

Richard has been an investor and partner with one of the world’s leading private equity and early-mid market companies focused on technology and services in life sciences and healthcare, investing and providing M&A, operational and advisory services. Over 30 M&A transactions completed since 2016 including many pivotal pharma services deals.

As an entrepreneur and seasoned life science executive, Todd has a 25year proven track record in building, growing, and leading successful organizations. Positions have included being a successful Business Owner, CEO, Board Member, Executive Director, and Executive with responsibilities throughout the United States and Europe. Todd played critical roles in a variety of venture investments, buyouts, acquisitions, and mergers – from target identification and due diligence through management of the ensuing integration processes.

Former Founder and CEO of Protein Solutions, Vice President, Sales and Marketing at Hemodyne and MolecularMD before becoming its Chief Operating Officer and eventually CEO. Dan is currently serving as the Senior Vice President, Commercial for Tasso Inc. in the Seattle Washington area which has developed innovative technologies designed to decentralize blood collection supporting applications in drug development, diagnostics and novel blood testing methods.

After co-founding Crosstree Capital Partners, Ryerson was Managing Director for Novumed Life Sciences (later acquired by E&Y Europe) leading the Global Strategic Advisory practice for pharmaceutical and medtech in- and out-licensing strategies. Ryerson has worked in the Life Sciences industry for more than 25 years, previously at OccamMD, William R. Hough & Co., and the Eckerd Drug Corporation. Ryerson holds a BS in Economics from Auburn University and a MBA from the University of South Florida.

Richard says that he has benefited immeasurably from working with a “tribe” of great people and organizations across multiple industries over his 30 year career – which he now channels and focuses into serving a portfolio of innovative investors and companies that are using technology to effect positive change in healthcare and life sciences.

Dan is a proven, authentic executive leader with over 20 years’ of experience in driving growth and building value in venture-backed health science organizations, including MolecularMD, an oncology focused molecular diagnostic company acquired by ICON plc. Throughout his career, Dan has excelled in matching novel technologies with validated market applications and thrives when working with passionate technology developers and early product champions. Dan is a customercentric commercial leader who inspires organizations to succeed by intimately aligning external market indicators with internal organizational vision and strategy.

1 E L P M A X E T U O LAY

Lorem ipsum dolor sit amet Cnsectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Cnsectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt est laborum.

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Duis aute irure • Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. • Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. • Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. • Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Ebitatestrum nonet as ni dolupta tionsequas ellorrum im lic totatinvenda dolorer chicimet utescitat estiam fuga. Cum untent optature nullam fuga. It endis re consentiam eos rerum aliasperrum dolupta is erum quid mint, et arum dolor si doleniam quae officiae pera nim solores re prerrovid modi ipici ipsam, sedit adi te. Ebitatestrum nonet as ni dolupta tionsequas ellorrum im lic totatinvenda dolorer chicimet utescitat estiam fuga. Cum untent optature nullam fuga. It endis re consentiam eos rerum aliasperrum dolupta is erum quid mint, et arum dolor si doleniam quae officiae pera nim solores re prerrovid modi ipici ipsam, sedit adi te.

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

I N N O V A T I O N S

I N

P H A R M A C E U T I C A L

Lorem ipsum dolor sit amet

D E V E L O P M E N T

“Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non officia deserunt mollit anim id est laborum.” —Excepteur sint occaecat cupidatat

Cnsectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Cnsectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt est laborum. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Safe

In Vivo

C Laore bs Se L rv ab O ice Lab ther Svcs s Central

Efficacy

a at nt D me r te ge as a M an M MS RI MF eT

Da Sc ta ien ce

Data Acqu is

Reg Affairs latory Regu ices Serv IRBs & /QC e QA plianc s Com tric me ta Da ces ien

Bio

P Su ub bm lish is in Me sio g & W dica ns riti l ng IntSyste Se D eg m rv at rat s ice a ion P Eng atie s age nt men SeClin t rv ica ice l Sites s T ri Executi al on Clinical Operations

CTMS Sourc ition Captu e re IRT Da An ta AI alytic s & M LT oo ls

Duis aute irure • Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. • Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. • Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. • Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

eISF

eCTD

Pharma Tech & Infosys

Reg & Safety Tech

Pub Mgmt

Reg

n tio era Opech T

Sit

istr

Statistics: Year Founded: 2000 Founded By: Name Surname Hame Surname Name Surname

ies

ria lT

dmin

t Te

tien

lA Tria

Cnsectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim

rt Vi

Genomics

Co Im re L ag ab in Ob g sR Os Co EK re L G ab

SocialMedia SocialMedia SocialMedia SocialMedia SocialMedia

eConsent

LMS

l ica

t all aly Smcule an o i e l Mo rgele B Laecu l d Mo lize ys a a s i ec As Sp

Name of Company Company Address Information +1-000-0000 (Please follow this format) email@address.com

companyurl.com 8

2 E L P M A X E T U O LAY

UNIVERSAL LABORATORY SUNT QUATUR AUTE SITAM, OMMOD MAXIMINT VOLOR PLA VOLUPTIAM EICIDERUM FUGIASSUS, AS SIT, OFFICIET AS SECULLATEM ARUM. Lorem ipsum dolor sit amet Cnsectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex et quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt est laborum. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Aliaeceprepe minum aceptat earuptatae sunducieniam faciendae nim restint re ped etum et landis ex et aliquam et quibus assiminto

quiam, quunt magnam quam quam repudant, il eostibus, quiatem laces sunt molor as ati quatem et et, ommoditaquod quae Ebitatestrum nonet as ni dolupta tionsequas ellorrum im lic totatinvenda dolorer chicimet utescitat estiam fuga. Cum untent optature nullam fuga. It endis re consentiam eos rerum aliasperrum dolupta is erum quid mint, et arum dolor si doleniam quae officiae pera nim solores re prerrovid modi ipici ipsam, sedit adi te. Ebitatestrum nonet as ni dolupta tionsequas ellorrum im lic totatinvenda dolorer chicimet utescitat estiam fuga. Cum untent optature nullam fuga. It endis re consentiam eos rerum aliasperrum dolupta is erum quid mint, et arum dolor si solores re prerrovid modi ipici ipsam, sedit adi te. Maxim ariorendia nonseque lacidunt vendis ut volupta tempore et repudae erferio rporro beria num faccaerum ad quam veliciatem hil magni corecep udaeperovit faccum quamustrum qui dis doluptat.

Ebitatestrum nonet as ni dolupta tionsequas ellorrum im lic totatinvenda dolorer chicimet utescitat estiam fuga. Ebitatestrum nonet as ni dolupta tionsequas ellorrum im lic totatinvenda dolorer chicimet utescitat estiam fuga. Cum untent optature nullam fuga. It endis re consentiam eos rerum aliasperrum dolupta is erum quid mint, et arum dolor si doleniam quae officiae pera nim solores re prerrovid modi ipici ipsam, sedit adi te. Ebitatestrum nonet as ni dolupta tionsequas ellorrum im lic totatinvenda dolorer chicimet utescitat estiam fuga. Cum untent optature nullam fuga. It endis re consentiam eos rerum aliasperrum dolupta is erum quid mint, et arum dolor si doleniam quae officiae pera nim solores re prerrovid modi ipici ipsam, sedit adi te. Ebitatestrum nonet as ni dolupta tionsequas ellorrum im lic totatinvenda dolorer chicimet utescitat estiam fuga. Cum untent optature nullam fuga. It endis re consentiam eos rerum aliasperrum dolupta is erum quid mint, et arum dolor si doleniam qua

I N N O V A T I O N S

I N

P H A R M A C E U T I C A L

D E V E L O P M E N T

Lorem ipsum dolor sit amet Cnsectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Cnsectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Safe

In Vivo

C Laore bs Se L rv ab O ice Lab ther Svcs s Central

Efficacy

a at nt D me r te ge as a M an M MS RI MF eT

Da Sc ta ien ce

Data Acqu is

Reg Affairs latory Regu ices Serv IRBs & /QC e QA plianc Com cs i r t me ta Da ces ien

Bio

P Su ub bm lish is in Me sio g & W dica ns riti l ng IntSyste Se D eg m rv at rat s ice a ion Eng Patie s age nt men SeClin t rv ica ice l Sites s T ri a Executi l on Clinical Operations

CTMS Sourc ition Captu e re IRT Da An ta AI alytic s & M LT oo ls

eISF

eCTD

Pharma Tech & Infosys

Reg & Safety Tech

Pub Mgmt

Reg

ti era Opech T

Sit

istr

Statistics: Year Founded: 2000 Founded By: Name Surname Hame Surname Name Surname

ies

ria lT

dmin

t Te

tien

lA Tria

rt Vi

Genomics

Co Im re L ag ab in Ob g sR Os Co EK re L G ab

SocialMedia SocialMedia SocialMedia SocialMedia SocialMedia

eConsent

LMS

a tic

all aly Smcule an o i e l Mo rgele B Laecu l d Mo lize ys a a s i ec As Sp

Name of Company Company Address Information +1-000-0000 (Please follow this format) email@address.com

companyurl.com 10

3 E L P M A X E T U O MAGIC LAY MEDICAL SUNT QUATUR AUTE SITAM, OMMOD MAXIMINT VOLOR PLA VOLUPTIAM EICIDERUM FUGIASSUS, AS SIT, OFFICIET AS SECULLATEM ARUM.

Mene vel int lab iumet Aliaeceprepe minum aceptat earuptatae sunducieniam faciendae nim restint re ped etum et landis ex et aliquam et quibus assiminto quiam, quunt magnam quam quam repudant, il eostibus, quiatem laces sunt molor as ati quatem et et, ommoditaquod quae maxim ariorendia nonseque lacidunt vendis ut volupta tempore et repudae erferio rporro beria num faccaerum ad quam veliciatem hil magni corecep udaeperovit faccum quamustrum qui dis doluptat. Ebitatestrum nonet as ni dolupta tionsequas ellorrum im lic totatinvenda dolorer chicimet utescitat estiam fuga. Cum untent optature nullam fuga. It endis re consentiam eos rerum aliasperrum dolupta is erum quid mint, et arum dolor si doleniam quae officiae pera nim solores re prerrovid modi ipici ipsam, sedit adi te.

I N N O V A T I O N S

I N

P H A R M A C E U T I C A L

D E V E L O P M E N T

Duis aute irure • Aliaeceprepe minum aceptat earuptatae sunducieniam • Faciendae nim restint re ped etum et landis ex et aliquam et quibus assiminto quiam. • Qquunt magnam quam quam repudant, il eostibus, quiatem laces sunt • Molor as ati quatem et et, ommoditaquod quae maxim ariorendia nonseque • Lacidunt vendis ut volupta tempore et repudae erferio rporro • Beria num faccaerum ad quam • Veliciatem hil magni corecep udaeperovit faccum quamustrum qui dis doluptat. • Ebitatestrum nonet as ni dolupta tionsequas ellorrum im lic totatinvenda dolorer chicimet utescitat estiam fuga. • Cum untent optature nullam fuga. It endis re consentiam eos rerum • Aliasperrum dolupta is erum quid mint • Eet arum dolor si doleniam quae officiae pera nim solores re • Prerrovid modi ipici ipsam, sedit adi te. • Um evelescimus rem hictur? Quid ma desequas

Safe

In Vivo

C Laore bs Se L rv ab O ice Lab ther Svcs s Central

Efficacy

CTMS Sourc Captu e re IRT Da An ta AI alytic s & M LT oo ls

occaecat cupidatat

a at nt D me r te ge as a M an M MS RI MF eT

Da Sc ta ien ce

Data Acqu isitio n

Reg Affairs latory Regu ices Serv IRBs & /QC e QA plianc s Com tric me ta Da ces ien

Bio

P Su ub bm lish is in Me sio g & W dica ns riti l ng IntSyste Se D eg m rv at rat s ice a ion P Eng atie s age nt men SeClin t rv ica ice l Sites s T ri Executi al on Clinical Operations

Excepteur sint occaecat cupidatat non officia deserunt mollit anim id est laborum.” —Excepteur sint

eISF

eCTD

Pharma Tech & Infosys

Reg & Safety Tech

Pub Mgmt

Reg

n tio era Opech T

Sit

istr

Statistics: Year Founded: 2000 Founded By: Name Surname Hame Surname Name Surname

ies

ua ls

ria lT

tien

t Te

dmin

lA Tria

rt Vi

Genomics

Co Im re L ag ab in Ob g sR Os Co EK re L G ab

SocialMedia SocialMedia SocialMedia SocialMedia SocialMedia

eConsent

LMS

l ica

t all aly Smcule an o i e l Mo rgele B Laecu l d Mo lize ys a a s i ec As Sp

Name of Company Company Address Information +1-000-0000 (Please follow this format) email@address.com

companyurl.com 12

I N N O V A T I O N S

I N

P H A R M A C E U T I C A L

Heading and Sub=heading

Company profile 500-550 words

D E V E L O P M E N T

I N N O V A T I O N S

I N

P H A R M A C E U T I C A L

D E V E L O P M E N T

Selection of Images

AR Button

Company Logo

Social Media Handles

Company Description 50 words Website address

LE P M XA E R VIDE I D TER P A CH

CHAPTER DIVIDER

INNOVATIONS OF THE FUTURE

“Minds are like parachutes; they only function when open.” —THOMAS DEWAR

I N N O V A T I O N S

I N

P H A R M A C E U T I C A L

D E V E L O P M E N T

INDUSTRY TAXONOMY An integral part of the project is the visual representation of your companies services and capabilities. You can either mark your capabilities within Pharmaceutical Development utilizing a proprietary industry classification infographic on the printable copy of the Industry Genome or alternatively use the form on this link to select your capabilities.

CTMS So ition Caputrce ure IRT Da An ta AI alytic s & M LT oo ls

Reg Affairs latory Regu ices Serv IRBs & /QC e QA plianc s Co m tric me ta Bio Da ces ien

Safe

In Vivo

Da Sc ta ien ce

Pharma Tech & Infosys

Reg & Safety Tech

t era Opech T

Sit

istr

ria lT

S ch

t Te tien

dmin

lA Tria

rt Vi

ion

Co Im re L ag ab in Ob g sR Os Co EK re L G ab

Pub Mgmt

Reg

Genomics

eConsent

LMS

ic lyt

all a Smcule an o i e l Mo rgele B Laecu l d Mo lize ys ia ssa c e A Sp

eCTD

C Laore bs Se L rv ab O ice Lab ther Svcs s Central

Efficacy

a at ent D er gem t as na M a M MS I R MF T e eISF

Data Acqu is

P Su ub bm lish is in Me sio g & W dica ns riti l ng S y Int ste Se D eg m rv at rat s ice a ion Eng Patie s age nt SeClin men t rv ica ice l Sites s T Executrial ion Clinical Operations

ies

I N N O V A T I O N S

I N

P H A R M A C E U T I C A L

D E V E L O P M E N T

INDUSTRY TAXONOMY GLOSSARY OF TERMS Clinical Services

• Core Laboratories - A core lab typically serves researchers working in R&D laboratories. Core labs frequently are subject matter experts when it comes to certain equipment and/ or techniques and is used by independent research labs to conduct highly specialized/technical assessments.

Clinical services are the medical, diagnostic, and therapeutic services provided directly to the patients that are currently enduring health conditions. • Trial Execution - Trial execution is the initiation of conducting experiments or observations on human participants for biomedical or behavioral research studies. These studies are specifically designed to discover the outcomes of new studies or interventions.

• Bioanalytical Laboratory Testing - A place, establishment or institution organized and operated primarily for performing chemical, microscopic, serologic, parasitologic, bacteriologic or other tests, by the practical application of one or more of the fundamental sciences to material originating from the human body, for the purpose of obtaining scientific data which may be used as an aid to ascertain the organism’s state of health.

• Data Services - Clinical data services allow for standardized and centralized end-to-end data collection, analyzation and publication to ensure a seamless, efficient trial process and drug approval.

• In Vivo Laboratory Testing - Medical tests and/or experiments or procedures that are done on (or in) a living organism, such as a laboratory animal or human. In vivo studies are conducted to look at the actual effect on how the living organism (body) will respond.

• Regulatory Services - Regulatory services are conducted in an organization or clinical trials in order to provide guidance for the company and make sure that they are following the legal guidelines and policies in regard to its daily business processes.

Pharma Tech & Infosys Software, technology, eclinical solutions, and data subscription services related to the development of drugs.

Laboratory Services A facility for the biological, microbiological, serologic, chemical, hematology, immunohematologic, biophysical, cytologic, pathologic, or other examination of materials derived from the human body for the purpose of providing information for diagnosing, preventing, or treating disease or impairment of, or assessment of humans.

• Data Acquisition - Data Acquisition and Repositories tools refer to technology that is utilized to capture, store, and analyze data used in clinical trials. • Regulatory and Safety Tech - Technology systems and solutions used to manage regulatory affairs, pharmacovigilance and safety requirements in clinical trials.

• Genomic Testing - The process of observing an entire genome (all the genes that make up an organism). Genomic testing evaluates all a person’s genes, rather than focusing on a specific gene, or set of genes. Genomic testing looks broadly for gene alterations, or harmful changes, anywhere in the genetic code.

• Operations Tech - Technology and related solutions used in the execution of clinical trial operations. • Data Science Tools – Tools used for the analysis, management, and presentation of data relating to clinical trials.

• Central Laboratories - A place, establishment or institutional laboratory that is responsible for conducting and consolidating laboratory testing, reporting and data originating in different clinical sites in order to standardize analytical platforms, kits, techniques and reference values allowing for the creation of harmonized processes and more consistent assessments.

I N N O V A T I O N S

I N

P H A R M A C E U T I C A L

D E V E L O P M E N T

AR VIDEO Arguably the coolest thing about the INNOVATE® series is its embedded Augmented Reality Video. This is the future of publishing—especially when AR wearables like Magic Leap, Hololens, Meta, ODG, and Intel’s Vaunt come into their own in the next couple of years. With the AR-video technology, one of the images on your spread comes to life as a video, viewable right on readers’ cellphone screens. The video can also be updated after the book has been printed.

IT’S A KIND OF MAGIC...

DOWNLOAD THE GLOBAL VILLAGE AR APP TO VIEW 100 AUGMENTED REALITY VIDEOS IN THIS BOOK! To experience the future of print, download the Global Village AR App from the IOS or Android App stores. Open the App and hold it about 30cm above any page that contains an image with the “play” Icon.

Make sure your back camera is pointing at the page. Click the Play button that appears onscreen and immerse yourself in the latest updated content with reference to that page.

I N N O V A T I O N S

I N

P H A R M A C E U T I C A L

EMBOSSED COVERS The INNOVATE® series’ matte black covers are the perfect canvas for your company’s logo. The shape of the logo is pressed into the cover itself and then filled in with silver foiling, in a process called embossing. It’s an elegant way to personalize your INNOVATE® copies.

D E V E L O P M E N T

I N N O V A T I O N S

I N

P H A R M A C E U T I C A L

OPTIONAL BOOK PACKAGES Innovations in Pharmaceutical Development books are going to be retailed for $125 each following publication. Sales will be both hardcopy and in eBook format. Global Village is offering participants who pre-order the books a 20% discount at $100 each. Additionally, Global Village is offering a Participant Package available for profiled companies who are interested in better leveraging their selection and exposure for this prestigious project with silver foil embossed logos, and media promotion kits. Participant Package: $2,500 • 25 personalized copies of the book (your company’s Silver Foil stamped logo on the Front Cover) • Social Media Promotion Kit (Images, callouts, etc.), a $450 value. Please inquire about any of these additional products and promotions: • Further discounting for book orders greater than 25 (including embossed logos) • Company profile page reprints • Social Media Promotion Kit (Images, callouts, etc.) • Award Plaque(s) • Specialized Gift Mailing Boxes • AR Video

D E V E L O P M E N T

I N N O V A T I O N S

I N

P H A R M A C E U T I C A L

The team behind Global Village Publishing has been publishing artfully designed Coffee Table Books to showcase different cities and industries around the world for the past 15 years. With an impressive 200 books in 62 different countries, their latest series focusing on Innovation has grown exponentially over the past 3 years connecting Innovators from cities and countries all around the world. They are working hard at building a network of Innovators around the world to connect and collaborate on building a better tomorrow.

“The secret to our success is that we treat each of our books as a work of art. This is not just a book of success stories - it is a beautifully designed centerpiece for any desk or coffee table with large vivid images and inspirational stories of Innovation. This is a book that will be given out as gifts and proudly displayed for years to come” – Callie Van Graan, Chief Operating Officer, Global Village Publishing

D E V E L O P M E N T